Volume 8.03 | Jan 28

Mammary Cell News 8.03 January 28, 2016
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  MCN on Twitter
 
TOP STORY
Groundbreaking Collaborative Breast Cancer Study Aims to Unlock the Doors of Individualized Patient Care with Big Data
The Intensive Trial of OMics in Cancer deeply characterizes and tracks the molecular features of a patient’s tumor, aggregates experts to generate hypotheses regarding treatments that are predicted to be beneficial, allows these predictions to be tested in the patient, and learns from these experiences to help future patients. [Press release from National Comprehensive Cancer Network discussing online publication in Journal of the National Comprehensive Cancer Network] Press Release | Full Article
Learn to Enumerate Mammospheres & Tumorspheres Cultured in MammoCult: Watch Procedure Now
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Cross-Kingdom Inhibition of Breast Cancer Growth by Plant miR159
Scientists found that Western donor sera contained the plant microRNA miR159, whose abundance in the serum was inversely correlated with breast cancer incidence and progression in patients. [Cell Res] Full Article

Rad51c– and Trp53 tumor-Double-Mutant Mouse Model Reveals Common Features of Homologous Recombination-Deficient Breast Cancers
Researchers demonstrated that deletion of Rad51c invariably requires inactivation of the Trp53 tumor suppressor (TP53 in humans) to produce mammary carcinomas in 63 percent of female mice. [Oncogene] Abstract

Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-Dependent Growth, Survival and Sensitivity towards Metformin in Breast Cancer Bone Metastasis
The authors investigated Runt-related transcription factor (Runx2) role in cell growth and metabolic signaling in bone-seeking breast cancer cells. They performed systemic inoculation of control or (Runx2) knockdown invasive MDA-MB-231 cells in NOD/SCID mice, and compared parental and bone-derived variants for phenotypic and molecular alterations. [Oncogene] Abstract

CDK9 Inhibitors Selectively Target Estrogen Receptor-Positive Breast Cancer Cells through Combined Inhibition of MYB and MCL-1 Expression
Researchers examined the effects of CDK9i on breast cancer cells and the involvement of MYB in these effects. Estrogen receptor-positive (ER+ve) breast cancer cell lines including MCF-7 were much more sensitive to killing by CDK9i than ER-ve/MYB-ve cells. [Oncotarget] Full Article

The Dual Function of PRMT1 in Modulating Epithelial-Mesenchymal Transition and Cellular Senescence in Breast Cancer Cells through Regulation of ZEB1
Scientists showed that the epithelial-mesenchymal transition program induced by protein arginine methyltransferase 1 (PRMT1) endowed the human mammary epithelial cells with cancer stem cell properties. Moreover, PRMT1 promoted the migratory and invasive behaviors in breast cancer cells. [Sci Rep] Full Article

Correlating Confocal Microscopy and Atomic Force Indentation Reveals Metastatic Cancer Cells Stiffen during Invasion into Collagen I Matrices
Investigators found that actively invading and fully embedded cells are significantly stiffer than cells remaining on top of the collagen, a clear example of phenotypical change in response to the three-dimensional environment. [Sci Rep] Full Article

X-Linked Inhibitor of Apoptosis Protein Mediates Tumor Cell Resistance to Antibody-Dependent Cellular Cytotoxicity
Investigators demonstrated that the most potent caspase inhibitor, X-linked inhibitor of apoptosis protein, overexpressed in inflammatory breast cancer, drives resistance to antibody-dependent cellular cytotoxicity mediated by cetuximab (anti-EGFR) and trastuzumab (anti-HER2). [Cell Death Dis] Full Article

Combined Niclosamide with Cisplatin Inhibits Epithelial-Mesenchymal Transition and Tumor Growth in Cisplatin-Resistant Triple-Negative Breast Cancer
Scientists found that niclosamide or combination with cisplatin inhibited both 231-CS and 231-CR cell proliferation in vitro. In addition, niclosamide reversed the epithelial-mesenchymal transition phenotype of 231-CR by downregulation of snail and vimentin. [Tumour Biol] Abstract

Molecular Characterization of Irinotecan (SN-38) Resistant Human Breast Cancer Cell Lines
Scientists established breast cancer (BC) cell lines with acquired or de novo resistance to SN-38, by exposing the human BC cell lines MCF-7 and MDA-MB-231 to either stepwise increasing concentrations over 6 months or an initial high dose of SN-38 (the active metabolite of irinotecan), respectively. [BMC Cancer] Full Article

Autophagy Mediated by Arginine Depletion Activation of the Nutrient Sensor GCN2 Contributes to Interferon-γ-Induced Malignant Transformation of Primary Bovine Mammary Epithelial Cells
Scientist provide the first evidence of the correlation between IFN-γ treatment, autophagy and malignant transformation and of the mechanism underlying IFN-γ-induced autophagy and subsequent malignant transformation in primary bovine mammary epithelial cells. [Cell Death Discov] Full Article

CLINICAL RESEARCH

Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients with Advanced Breast Cancer
Investigators analyzed serum human epidermal growth factor 2 (HER2) and tissue HER2 data from 1,902 patients who were randomly assigned to receive lapatinib or control in the trials EGF30001, EGF30008, and EGF100151. [J Clin Oncol] Abstract

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
Forty-five patients enrolled in nine dose cohorts plus five in an expansion cohort at the highest dose level and recommended phase II dose, 300 mg BID. Maximum tolerated dose of veliparib was not reached. [Clin Cancer Res] Abstract

See Who's Published: Leading Breast Cancer Researchers Use MammoCult™
 
REVIEWS
Epigenomic Regulation of Oncogenesis by Chromatin Remodeling
The authors summarize the recent developments and current state of the dysregulation of the chromatin remodeling components as the driving mechanism underlying the growth and progression of human tumors. [Oncogene] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Register for Precision: Breast Cancer
 
INDUSTRY NEWS
MetaStat Announces Successful Analytical Validation of its MenaCalc™ Cancer Diagnostic Platform
MetaStat, Inc. announced the successful completion of an analytical validation study of its MenaCalc™ clinical test, which demonstrated strong overall assay performance and precision with mean coefficient of variation of only 2.3%. MenaCalc™ is a next generation driver-based prognostic test to predict the risk of developing cancer metastasis in patients with invasive breast cancer, squamous cell carcinoma of the lung and a number of additional epithelial-based cancer tumors. [MetaStat, Inc.] Press Release

lifeIMAGE Acquires Mammosphere, an Innovative Network Enhancing Women’s Health Through Mammography Image Exchange
lifeIMAGE, the nation’s largest medical image exchange platform that enables imaging data interoperability across healthcare networks, providers and patients, announced that it has acquired Mammosphere, the leading national medical exchange network specializing in mammography and women’s imaging. [lifeIMAGE Inc.] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells?
Request your free wallchart.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW IMPAKT 2016 Breast Cancer Conference
May 12-14, 2016
Brussels, Belgium

Visit our events page to see a complete list of events in the mammary cell community.
 
JOB OPPORTUNITIES
NEW Professorship – Clinical Breast Cancer Research (University of Leeds)

NEW Clinical Pathways Associate – Cancer Therapeutics (Fred Hutchinson Cancer Research Center)

Clinical Researcher – Breast Cancer (Massachusetts General Hospital-Cancer Center)

Post-Doc Fellowship – Breast Cancer Development (University of Pennsylvania)

Post-Doc Fellowship/PhD Studentship – Cancer Cell-Tumor Microenvironment Interactions (University of Helsinki)

Academic Surgical Pathologist – Breast Pathology (Northwestern University)

Post-Doc Fellowship – Breast Cancer Functional Genomics (University of Cambridge)

Post-Doc Fellowship – Breast Cancer Translational Research (University of Bern)

Post-Doc Fellowship – Breast/Ovarian Cancer Therapeutics (Fred Hutchinson Cancer Research Center)

Post-Doc Fellowship – Epidemiologist (German Cancer Research Center)

Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center)

PhD Researcher – Cancer Signaling/Epigenetics/Tumor Biology (Institut Curie)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us